STOCK TITAN

Zymeworks To Host First Quarter 2023 Results Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company focused on developing innovative biotherapeutics, will report its Q1 2023 financial results on May 8, 2023, after market close. Following this announcement, Zymeworks will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Investors can access the live event and recordings through Zymeworks’ website.

Founded with a mission to address challenging cancers and other serious diseases, Zymeworks specializes in antibody-based therapies using its proprietary Azymetric™ technology. The company is advancing its lead candidate, zanidatamab, and next-generation product zanidatamab zovodotin (ZW49), both targeting HER2-expressing cancers.

Positive
  • None.
Negative
  • None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2023 at 4:30 p.m. Eastern Time (ET).

The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

Investor Inquiries:

Jack Spinks

Director, Investor Relations

(604) 678-1388

ir@zymeworks.com



Media Inquiries:

Diana Papove

Director, Corporate Communications

(604) 678-1388

media@zymeworks.com

Source: Zymeworks Inc.

FAQ

What are Zymeworks' Q1 2023 financial results announcement details?

Zymeworks will announce its Q1 2023 financial results after market close on May 8, 2023.

When will Zymeworks hold its conference call to discuss financial results?

The conference call will take place on May 8, 2023, at 4:30 p.m. ET.

Where can I find the webcast for Zymeworks' Q1 2023 financial results?

The webcast will be available live and for replay on Zymeworks' website.

What is zanidatamab developed by Zymeworks?

Zanidatamab is a HER2-targeted bispecific antibody currently being evaluated in clinical trials for HER2-expressing cancers.

What is zanidatamab zovodotin (ZW49)?

ZW49 is a HER2-targeted antibody-drug conjugate developed by Zymeworks, currently in Phase 1 clinical trials.

Zymeworks Inc.

NASDAQ:ZYME

ZYME Rankings

ZYME Latest News

ZYME Stock Data

914.00M
66.64M
0.08%
101.32%
6.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MIDDLETOWN